6533b835fe1ef96bd129fff2

RESEARCH PRODUCT

Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients. The ERIC‐HTA study

Jorge NavarroJosep RedónLuis Cea‐calvoJosé V. LozanoCristina Fernández-pérezÁLvaro BonetJorge González‐estebanNull On Behalf Of The Group Of Investiga

subject

Malemedicine.medical_specialtyRenal functionDiseasePrimary careInternal medicinePrevalenceInternal MedicinemedicineHumansAgedMetabolic SyndromeLeft ventricle hypertrophybusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseTarget organ damageOrgan damageCross-Sectional StudiesCardiovascular DiseasesSpainHypertensionCardiologyFemaleHypertrophy Left VentricularMetabolic syndromeCardiology and Cardiovascular MedicinebusinessBody mass index

description

The aim of this study is to assess the relationship among metabolic syndrome (MS), target organ damage (TOD) and established cardiovascular disease (CVD) in non-diabetic hypertensive elderly patients. ERIC-HTA is cross-sectional, multicentre study carried out in primary care, on hypertensive patients aged 55 or older. MS was defined by the NCEP-ATP III criteria, using body mass index (28.8 kg/m(2)) instead of abdominal perimeter. In 8331 non-diabetic hypertensive patients (3663 men and 4668 women, mean age 67.7 years), the prevalence of MS was 32.6% (men: 29.0%; women: 36.8%). A linear association was observed between a greater number of components of MS and a greater prevalence of left ventricle hypertrophy (LVH) on the electrocardiogram (p0.001), impaired kidney function (p0.001) and established CVD (p = 0.001). In a multivariate model, MS in non-diabetic hypertensive patients was related to a greater prevalence of LVH (OR 1.31 [95% CI: 1.15-1.48]), impaired kidney function (OR 1.45 [95% CI: 1.29-1.63]) and established CVD (OR 1.22 [95% CI: 1.08-1.37]). This relationship persisted after stratifying by gender. In conclusion, in this elderly non-diabetic hypertensive population, the presence of MS was independently related to a greater prevalence of hypertensive TOD and established CVD, suggesting a role of MS as a cardiovascular risk marker in hypertension.

https://doi.org/10.1080/08037050701217817